<DOC>
	<DOCNO>NCT00508924</DOCNO>
	<brief_summary>This phase II multi-centre study 140 patient undergoing elective PCI obtain information dose-response argatroban pharmacodynamic marker assess anticoagulation , safety efficacy argatroban reference unfractionated heparin , combination dual antiplatelet therapy .</brief_summary>
	<brief_title>Study Safety Effectiveness Three Doses Argatroban Anticoagulant Percutaneous Coronary Intervention ( PCI )</brief_title>
	<detailed_description>This phase II multi-centre study Europe patient stable coronary artery disease troponin negative unstable angina undergo elective PCI , obtain information safety effect various pharmacodynamic marker , three dos argatroban combination clopidogrel aspirin , assess result argatroban unfractionated heparin , use combination clopidogrel aspirin , clinical outcome , adequacy anticoagulation , various pharmacodynamic marker ( approximately 35 patient per group ) .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Argatroban</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Male female ( woman child bear potential must negative pregnancy test prior entry study ) Aged 18 year Diagnosis stable coronary artery disease ( CAD ) unstable angina ( troponin negative , i.e . within normal range study site ) low moderate anatomic risk requirement elective percutaneous coronary angioplasty stent insertion approve device one de novotreated restenotic lesion native vessel Signed write informed consent Any condition , investigator 's opinion , contraindicates use argatroban , heparin clopidogrel endangers patient he/she participate study . Known cirrhosis , hepatitis , clinically significant hepatic disorder , history hepatic disorder . Hepatic disorder define level liver function test ( bilirubin , Aspartate Aminotransferase ( Serum Glutamate Oxaloacetate Transaminase ) ( AST ( SGOT ) ) , Alanine Aminotransferase ( Serum Glutamate Pyruvate Transaminase ) ( ALT ( SGPT ) ) great 3.0 time upper limit normal range local laboratory . Patients currently take aspirin Renal insufficiency , define serum creatinine great 2.0 mg/dL ( great 177mmol/L ) Platelets less 125,000/ml If already take form heparin prior study enrolment , Activated Partial Thromboplastin Time ( aPTT ) equal great 35 sec ACT great 160 sec Use low molecular heparin ( LMWH ) 12 h prior PCI If take oral anticoagulant medication prior study enrolment , International Normalised Ratio ( INR ) great 1.2 Q wave MI cardiogenic shock thrombolytic therapy within 72 h study dose Use Glycoprotein IIb / IIIa ( GPIIb/IIIa ) inhibitor within prior 3 week Documented coagulation disorder bleed diathesis Lumbar puncture within past 2 week History previous cerebral aneurysm , haemorrhagic stroke , thrombotic stroke within past 6 month Active , uncontrolled peptic ulcer disease gastrointestinal bleeding genitourinary bleeding within 3 month prior study enrolment Major surgery , serious trauma , puncture noncompressible vessel , biopsy parenchymal organ within prior 2 month Planned staged procedure , plan rotational atherectomy , directional coronary atherectomy , brachytherapy , thrombectomy catheter Planned surgical intervention study procedure within next 7 day Presence great 50 % stenosis unprotected leave main coronary artery Severe peripheral vascular disease , preclude femoral access History vasculitis Uncontrolled hypertension define great 180/120 mmHg Pregnancy ( exclusion routine urine test ) Lactating woman Woman child bear age use accepted contraceptive method Participation clinical trial investigational product within 3 month prior study enrolment Terminally ill patient life expectancy &lt; 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Argatroban</keyword>
	<keyword>Direct thrombin inhibitor</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Activated clotting time</keyword>
	<keyword>PCI</keyword>
	<keyword>ACT</keyword>
</DOC>